Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Location

MS status

Recruitment Status

Phase

Drugs

Prior Immunotherapy Allowed

NCT ID

Title key word search

Date Trial Added

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Phase	Date Added	Location	Prior IO Allowed	CRC-directed	Status	Drugs	Tags
NCT ID NCT03190941	TitleAdministering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients	Phase Phase 1, Phase 2	Date Added 2017-06-19	Location Maryland, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs Anti-KRAS G12V mTCR PBL, Cyclophosphamide, Fludarabine, High-dose Aldesleukin	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03170960	TitleStudy of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors	Phase Phase 1	Date Added 2017-05-31	Location Arizona, United States California, United States Colorado, United States Connecticut, United States District of Columbia, United States Florida, United States Georgia, United States Illinois, United States Kansas, United States Kentucky, United States Louisiana, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States Nebraska, United States Nevada, United States New Jersey, United States New York, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Texas, United States Utah, United States Virginia, United States Australia Belgium France Germany Italy Netherlands Spain United Kingdom	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs Atezolizumab, Cabozantinib	Tags MSS/ MMRp
NCT ID NCT03155061	TitleStudy of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors	Phase Phase 1	Date Added 2017-05-16	Location Japan	Prior IO Allowed Yes	CRC-directed No	Status Active, not recruiting	Drugs ONO-4538, ONO-4578, Opdivo	Tags MSS/ MMRp
NCT ID NCT03104439	TitleNivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer	Phase Phase 2	Date Added 2017-04-07	Location Massachusetts, United States	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs Ipilimumab, Nivolumab, Opdivo, Yervoy	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03096093	TitleInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer	Phase Phase 1, Phase 2	Date Added 2017-03-30	Location United Kingdom	Prior IO Allowed Yes	CRC-directed No	Status Active, not recruiting	Drugs ACIT-1	Tags MSS/ MMRp
NCT ID NCT03093116	TitleA Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements	Phase Phase 1, Phase 2	Date Added 2017-03-28	Location California, United States Colorado, United States District of Columbia, United States Florida, United States Georgia, United States Illinois, United States Louisiana, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States Australia Belgium Canada China Denmark France Germany Hong Kong Hungary Italy Japan Korea, Republic of Netherlands Poland Singapore Spain Taiwan United Kingdom	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs Oral repotrectinib (TPX-0005)	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03088150	TitleCOLLISION Trial – Colorectal Liver Metastases: Surgery vs Thermal Ablation	Phase Phase 3	Date Added 2017-03-23	Location Netherlands	Prior IO Allowed Yes	CRC-directed Yes	Status Unknown status	Drugs	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03069469	TitleStudy of DCC-3014 in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor	Phase Phase 1, Phase 2	Date Added 2017-03-03	Location California, United States Colorado, United States Florida, United States Massachusetts, United States New York, United States Oregon, United States Tennessee, United States Australia Canada France Italy Netherlands Poland Spain United Kingdom	Prior IO Allowed Yes	CRC-directed No	Status Active, not recruiting	Drugs DCC-3014	Tags MSS/ MMRp
NCT ID NCT03030378	TitlePembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors	Phase Phase 1	Date Added 2017-01-25	Location California, United States Colorado, United States Connecticut, United States Florida, United States Georgia, United States Iowa, United States Maryland, United States Massachusetts, United States Missouri, United States New Jersey, United States North Carolina, United States Ohio, United States Pennsylvania, United States Texas, United States Virginia, United States	Prior IO Allowed No	CRC-directed No	Status Active, not recruiting	Drugs Edodekin alfa, Pembrolizumab	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03013218	TitleA Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)	Phase Phase 1	Date Added 2017-01-06	Location Colorado, United States Connecticut, United States Massachusetts, United States Michigan, United States Washington, United States Korea, Republic of	Prior IO Allowed No	CRC-directed No	Status Active, not recruiting	Drugs 5-FU + Cisplatin, Evorpacept (ALX148), Pembrolizumab, Ramucirumab + Paclitaxel, Rituximab, Trastuzumab	Tags MSS/ MMRp

Showing 261 to 270 of 299 entries